Delving into the Latest Updates on Fat Emulsion(C14-24) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Fat Emulsion(C14-24), 大豆油/卵磷脂, 脂肪乳(C14-24)

+ [2]

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

esssential fatty acid deficiency

Inactive Indication-

Originator Organization

Fresenius Kabi Deutschland GmbH

Active Organization

Fresenius Kabi Deutschland GmbH

Fresenius Kabi SSPC Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (07 Oct 1975),

esssential fatty acid deficiency

Regulation-

Login to view timeline

To test the hypothesis that active BAT improves metabolic health by buffering postprandial metabolites plasma metabolites and energy expenditure will be compared in volunteers with and without active BAT. Both groups will receive test meals with protein, fat and carbohydrates separately, so that the individual impacts of these macronutrients on diet induced thermogenesis and the buffering function of BAT can be derived. BAT biopsies will be taken before and after the test meals for molecular analysis.

Start Date12 Oct 2023

Sponsor / Collaborator

Universitätsspital Basel

100 Clinical Results associated with Fat Emulsion(C14-24)

Login to view more data

100 Translational Medicine associated with Fat Emulsion(C14-24)

Login to view more data

100 Patents (Medical) associated with Fat Emulsion(C14-24)

Login to view more data

2,489

Literatures (Medical) associated with Fat Emulsion(C14-24)

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Investigation on concentration detection of turbid solution based on hemisphere sample cell and multidimensional spectroscopy

Article

Author: Ji, Wenlong ; Zheng, Huayan ; Xu, Yun ; Zhang, Jianxin

The study developed a hemisphere sample cell and constructed a multidimensional spectroscopy acquisition system to enhance the accuracy of detecting turbid solution with scattering properties. The system simultaneously captures absorption and scattering information from the tested samples. Monte Carlo simulation was employed to model the transmission light intensity distribution data from sample cells of various shapes. It was found that the hemisphere sample cell increases the dimensionality of transmission light intensity information and enables the acquisition of more scattering-related data. Furthermore, 46 samples of intralipid-20% solution with varying concentrations were examined. Models were constructed using partial least squares (PLS) regression with one-dimensional and two-dimensional light intensity distribution data. The results indicate that the model using two-dimensional light intensity distribution data significantly outperforms the model using one-dimensional data, reducing the root mean square error by 39.96% and increasing the correlation coefficient by 0.332%. Experimental results demonstrate that the multidimensional spectroscopic modeling method employing the hemisphere sample cell can significantly enhance the accuracy and speed of detecting chemical composition concentrations in turbid solution.

01 Dec 2024·Neuropeptides

Enteroendocrine cell-derived peptide YY signalling is stimulated by pinolenic acid or Intralipid and involves coactivation of fatty acid receptors FFA1, FFA4 and GPR119

Article

Author: Moodaley, Runisha ; Cox, Helen M. ; Tough, Iain R ; Cox, Helen M ; Tough, Iain R.

Long chain fatty acids are sensed by enteroendocrine L cells that express free-fatty acid receptors, including FFA1, FFA4 and the acylethanolamine receptor GPR119. Here we investigated the acute effects of single or multiple agonism at these G protein-coupled receptors in intestinal mucosae where L cell-derived peptide YY (PYY) is anti-secretory and acts via epithelial Y₁ receptors. Mouse ileal or colonic mucosae were mounted in Ussing chambers, voltage-clamped and the resultant short-circuit current (I_sc) recorded continuously. The agonists used were; FFA1, TAK-875 or AM-1638; for FFA4, Merck A; or for GPR119, AR231453, PSN632408 or AR440006. Their responses were compared with those of pinolenic acid (PA, a presumed dual FFA1/FFA4 agonist) and the lipid emulsion, Intralipid. The FFA1 agonist AM-1638 (EC₅₀ = 38.2 nM) was more potent than TAK-875 (EC₅₀ = 203.1 nM) but exhibited similar efficacy. GPR119 agonism (AR231453) pretreatment enhanced subsequent FFA1 (AM-1638 or TAK-875) and FFA4 (Merck A) signalling. PA (EC₅₀ = 298.2 nM) co-activated epithelial FFA1 and FFA4 and involved endogenous PYY Y₁/Y₂-receptor mechanisms but desensitisation was observed between PA and high GPR119 agonist concentrations. Apical Intralipid co-activated FFA1, FFA4 and GPR119 with a residual component not being attributable to PYY, or this trio of fatty acid receptors.

26 Nov 2024·Clinical Chemistry and Laboratory Medicine (CCLM)

Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances

Article

Author: Renaudineau, Yves ; Puissant-Lubrano, Bénédicte ; Sailler, Laurent

AbstractObjectivesThe quantification of functional C1 inhibitor activity (fC1-INH) is an important tool to diagnose bradykinin-mediated angioedema (AE), whether hereditary or acquired. For that an accurate assay is necessary, therefore we evaluated the analytical performances of a fC1-INH chromogenic assay (Berichrom®, Siemens) performed utilizing an Optilite turbidimeter (Binding Site).MethodsfC1-INH was quantified by means of the chromogenic assay Berichrom®. Internal quality controls were used to determine the precision of the assay. Stability under various storage and matrix conditions, uncertainty, linearity, interference (of hemolysis, lipemia, and icterus), agreement with the manual Technochrom® assay, and diagnostic performances were further evaluated on samples from patients and healthy donors.ResultsThe fC1-INH Berichrom® assay presented good performances regarding intra- and inter-assay precision (CV: 1.3–4.5 % and 3.0–6.0 %, respectively), expanded uncertainty (5.5 % at normal level and 12.5 % at the clinical threshold) and linearity (rho2>0.99: range 7–130 % activity). Addition of interfering substances (hemoglobin <16 g/L, intralipid® <12 g/L, and bilirubin <1 g/L) did not affect fC1-INH quantification. fC1-INH activity from healthy donors remained stable in citrate whole blood until 4 days at room temperature, and 7 days when plasma was collected. Agreement between the automated Berichrom® assay and the manual Technochrom® assay (n=47) was excellent as obtained with both quantitative (Deming regression and Bland–Altman difference plot) and qualitative (Kappa index=1) analyses. Finally, the diagnostic performance of the quantification of fC1-INH for AE evaluated on 81 patients revealed a sensitivity of 100 %, a specificity of 97.2 %, a positive predictive value of 83.3 % and a negative predictive value of 100 %.ConclusionsThe automated fC1-INH Berichrom® assay showed good performance, both at the analytical and diagnostic/clinical levels that allowed its usage in a clinical laboratory for C1-INH-dependent bradykinin-mediated AE research in combination with quantitative C1-INH and C4 determinations.

100 Deals associated with Fat Emulsion(C14-24)

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
esssential fatty acid deficiency	US	Fresenius Kabi Deutschland GmbH	07 Oct 1975

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2024	Not Applicable	-	-	Intralipid	zbrusrpvke(yrlvaymfzn) = zuuyabaocg ifmxfnamrn (opfnetjfaa ) View more	-	14 Jun 2024
				Saline	zbrusrpvke(yrlvaymfzn) = rekmfvbofb ifmxfnamrn (opfnetjfaa ) View more
NCT00672854 (TPN2, CTgov)	Phase 2/3	Dietary Supplement \| stress oxidative	100	Intralipid (Total Parenteral Nutrition (TPN) Given Intralipid 20%)	txojqygqos(abywvuczmg) = ogghyrmgoz yhfhqgwcex (kybcljlfnu, pwsgxvsiob - sctmdjoqlq) View more	-	01 Aug 2014
				ClinOleic (Total Parenteral Nutrition (TPN) Given ClinOleic 20%)	txojqygqos(abywvuczmg) = bfhcsoapmx yhfhqgwcex (kybcljlfnu, lnfwbapjqi - bpdirkfvlc) View more
NCT01096771 (CTgov)	Phase 2	Respiratory Distress Syndrome, Adult	14	ClinOleic (Experimental ClinOleic 20%)	zkdzptfdnv(vfuyhtrark) = eczfmxxijt bmlabbdsie (dlcuqnnvyy, qcilhafhjo - qyrvnrivuj) View more	-	26 May 2014
				Intralipid (Control: Intralipid 20%)	zkdzptfdnv(vfuyhtrark) = splhlxtzoz bmlabbdsie (dlcuqnnvyy, fanhlebogw - xzvtsxfcel) View more